176 related articles for article (PubMed ID: 21424594)
1. Insights into the binding modes of human β₃-adrenergic receptor agonists with ligand-based and receptor-based methods.
Jin F; Lu C; Sun X; Li W; Liu G; Tang Y
Mol Divers; 2011 Nov; 15(4):817-31. PubMed ID: 21424594
[TBL] [Abstract][Full Text] [Related]
2. Hierarchical virtual screening: identification of potential high-affinity and selective β(3)-adrenergic receptor agonists.
Saxena AK; Roy KK
SAR QSAR Environ Res; 2012 Jul; 23(5-6):389-407. PubMed ID: 22452658
[TBL] [Abstract][Full Text] [Related]
3. Modeling and simulation studies of human β3 adrenergic receptor and its interactions with agonists.
Sahi S; Tewatia P; Malik BK
Curr Comput Aided Drug Des; 2012 Dec; 8(4):283-95. PubMed ID: 22242799
[TBL] [Abstract][Full Text] [Related]
4. Insights into the conformational perturbations of novel agonists with β3-adrenergic receptor using molecular dynamics simulations.
Tewatia P; Agrawal N; Gaur M; Sahi S
Biochimie; 2014 Jun; 101():168-82. PubMed ID: 24508605
[TBL] [Abstract][Full Text] [Related]
5. Cryo-EM structure of the β3-adrenergic receptor reveals the molecular basis of subtype selectivity.
Nagiri C; Kobayashi K; Tomita A; Kato M; Kobayashi K; Yamashita K; Nishizawa T; Inoue A; Shihoya W; Nureki O
Mol Cell; 2021 Aug; 81(15):3205-3215.e5. PubMed ID: 34314699
[TBL] [Abstract][Full Text] [Related]
6. β(3)-Adrenoceptor agonists and (antagonists as) inverse agonists history, perspective, constitutive activity, and stereospecific binding.
Grazia Perrone M; Scilimati A
Methods Enzymol; 2010; 484():197-230. PubMed ID: 21036234
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel β3-adrenoceptor agonists using energetic analysis, structure based pharmacophores and virtual screening.
Tewatia P; Malik BK; Sahi S
Comb Chem High Throughput Screen; 2012 Sep; 15(8):623-40. PubMed ID: 22375887
[TBL] [Abstract][Full Text] [Related]
8. Desirable properties of β3-adrenoceptor agonists: implications for the selection of drug development candidates.
Michel MC; Cernecka H; Ochodnicky P
Eur J Pharmacol; 2011 Apr; 657(1-3):1-3. PubMed ID: 21315709
[TBL] [Abstract][Full Text] [Related]
9. Discovery of benzamides as potent human β3 adrenergic receptor agonists.
Zhu C; Kar NF; Li B; Costa M; Dingley KH; Di Salvo J; Ha SN; Hurley AL; Li X; Miller RR; Salituro GM; Struthers M; Weber AE; Hale JJ; Edmondson SD
Bioorg Med Chem Lett; 2016 Jan; 26(1):55-9. PubMed ID: 26590100
[TBL] [Abstract][Full Text] [Related]
10. A classification study of human β₃-adrenergic receptor agonists using BCUT descriptors.
Hao M; Li Y; Wang Y; Zhang S
Mol Divers; 2011 Nov; 15(4):877-87. PubMed ID: 21626288
[TBL] [Abstract][Full Text] [Related]
11. β(3)-Adrenoceptor ligand development history through patent review.
Perrone MG; Scilimati A
Expert Opin Ther Pat; 2011 Apr; 21(4):505-36. PubMed ID: 21410429
[TBL] [Abstract][Full Text] [Related]
12. Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.
Cheng F; Xu Z; Liu G; Tang Y
Eur J Med Chem; 2010 Aug; 45(8):3459-71. PubMed ID: 20537438
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of N-phenyl-(2-aminothiazol-4-yl)acetamides with phenoxypropanolamine moiety as selective β3-adrenergic receptor agonists.
Maruyama T; Onda K; Suzuki T; Hayakawa M; Takahashi T; Matsui T; Takasu T; Nagase I; Ohta M
Chem Pharm Bull (Tokyo); 2012; 60(5):647-58. PubMed ID: 22689403
[TBL] [Abstract][Full Text] [Related]
14. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
de Souza CJ; Burkey BF
Curr Pharm Des; 2001 Sep; 7(14):1433-49. PubMed ID: 11472270
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.
Igawa Y; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):177-83. PubMed ID: 23263450
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
Yuzlenko O; Kieć-Kononowicz K
J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
[TBL] [Abstract][Full Text] [Related]
17. Characterization of beta3-adrenergic receptor: determination of pharmacophore and 3D QSAR model for beta3 adrenergic receptor agonism.
Prathipati P; Saxena AK
J Comput Aided Mol Des; 2005 Feb; 19(2):93-110. PubMed ID: 16075304
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel and potent human and rat beta3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic acid.
Harada H; Hirokawa Y; Suzuki K; Hiyama Y; Oue M; Kawashima H; Kato H; Yoshida N; Furutani Y; Kato S
Chem Pharm Bull (Tokyo); 2005 Feb; 53(2):184-98. PubMed ID: 15684518
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of novel phenylethanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.
Maruyama T; Onda K; Hayakawa M; Suzuki T; Kimizuka T; Matsui T; Takasu T; Nagase I; Hamada N; Ohta M
Chem Pharm Bull (Tokyo); 2010 Apr; 58(4):533-45. PubMed ID: 20410638
[TBL] [Abstract][Full Text] [Related]
20. Insights into β
Luan J; Hu B; Wang H; Liu H; Wang S; Chen L; Li W; Wang J; Cheng M
Comput Biol Chem; 2023 Jun; 104():107836. PubMed ID: 36889141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
